These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 18806523

  • 1. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 3. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 4. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Feb; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
    Borer JS, Tardif JC.
    Am J Cardiol; 2010 Jan 01; 105(1):29-35. PubMed ID: 20102886
    [Abstract] [Full Text] [Related]

  • 6. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan 01; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 7. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb 01; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 8. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E, Bonadei I, D'Aloia A, Del Magro F, Piovanelli B, Bontempi L, Curnis A, Dei Cas L.
    Minerva Med; 2011 Oct 01; 102(5):373-9. PubMed ID: 22193347
    [Abstract] [Full Text] [Related]

  • 9. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb 01; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 10. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 01; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 11. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G.
    Adv Ther; 2010 Mar 01; 27(3):160-7. PubMed ID: 20419486
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
    López-Bescós L, Filipova S, Martos R.
    Cardiology; 2007 Mar 01; 108(4):387-96. PubMed ID: 17890862
    [Abstract] [Full Text] [Related]

  • 13. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 14. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug 27; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

  • 15. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Aug 27; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 16. Ivabradine: A Unique and Intriguing Medication for Treating Cardiovascular Disease.
    Nawarskas JJ, Bowman BN, Anderson JR.
    Cardiol Rev; 2015 Aug 27; 23(4):201-11. PubMed ID: 25839989
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M, Borer JS, Tardif JC.
    Cardiology; 2009 Dec 01; 114(2):116-25. PubMed ID: 19468225
    [Abstract] [Full Text] [Related]

  • 19. Drug insight: If inhibitors as specific heart-rate-reducing agents.
    Borer JS.
    Nat Clin Pract Cardiovasc Med; 2004 Dec 01; 1(2):103-9. PubMed ID: 16265314
    [Abstract] [Full Text] [Related]

  • 20. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.